205 related articles for article (PubMed ID: 30956097)
1. Prevalence of heterozygous familial hypercholesterolemia and combined hyperlipidemia phenotype in very young survivors of myocardial infarction and their association with the severity of atheromatous burden.
Rallidis LS; Kosmas N; Tsirebolos G; Rallidi M; Kiouri E; Kalpakos D
J Clin Lipidol; 2019; 13(3):502-508. PubMed ID: 30956097
[TBL] [Abstract][Full Text] [Related]
2. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label).
Braamskamp MJAM; Langslet G; McCrindle BW; Cassiman D; Francis GA; Gagne C; Gaudet D; Morrison KM; Wiegman A; Turner T; Miller E; Kusters DM; Raichlen JS; Martin PD; Stein EA; Kastelein JJP; Hutten BA
Circulation; 2017 Jul; 136(4):359-366. PubMed ID: 28592434
[TBL] [Abstract][Full Text] [Related]
3. Differences in phenotype, genotype and cardiovascular events between patients with probable and definite heterozygous familial hypercholesterolemia.
Cao YX; Zhou BY; Sun D; Li S; Guo YL; Zhu CG; Wu NQ; Gao Y; Xu RX; Liu G; Dong Q; Li JJ
Per Med; 2019 Nov; 16(6):467-478. PubMed ID: 31691639
[No Abstract] [Full Text] [Related]
4. Detecting familial hypercholesterolemia by serum lipid profile screening in a hospital setting: Clinical, genetic and atherosclerotic burden profile.
Scicali R; Di Pino A; Platania R; Purrazzo G; Ferrara V; Giannone A; Urbano F; Filippello A; Rapisarda V; Farruggia E; Piro S; Rabuazzo AM; Purrello F
Nutr Metab Cardiovasc Dis; 2018 Jan; 28(1):35-43. PubMed ID: 28958694
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein(a) level associates with coronary artery disease rather than carotid lesions in patients with familial hypercholesterolemia.
Sun D; Zhou BY; Zhao X; Li S; Zhu CG; Guo YL; Gao Y; Wu NQ; Liu G; Dong Q; Li JJ
J Clin Lab Anal; 2018 Sep; 32(7):e22442. PubMed ID: 29603377
[TBL] [Abstract][Full Text] [Related]
6. Polyvascular subclinical atherosclerosis in familial hypercholesterolemia: The role of cholesterol burden and gender.
Mattina A; Giammanco A; Giral P; Rosenbaum D; Carrié A; Cluzel P; Redheuil A; Bittar R; Béliard S; Noto D; Quartarone A; Averna M; Bruckert É; Gallo A
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1068-1076. PubMed ID: 31378630
[TBL] [Abstract][Full Text] [Related]
7. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.
Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G
Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356
[TBL] [Abstract][Full Text] [Related]
8. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.
Besseling J; Kindt I; Hof M; Kastelein JJ; Hutten BA; Hovingh GK
Atherosclerosis; 2014 Mar; 233(1):219-23. PubMed ID: 24529147
[TBL] [Abstract][Full Text] [Related]
9. Nine-year overview of dyslipidemia management in children with heterozygous familial hypercholesterolemia: a university hospital outpatient lipid clinic project in Northwestern Greece.
Benekos T; Kosmeri C; Vlahos A; Milionis H
J Pediatr Endocrinol Metab; 2020 Apr; 33(4):533-538. PubMed ID: 32084003
[TBL] [Abstract][Full Text] [Related]
10. Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle.
Shek A; Alieva R; Kurbanov R; Hoshimov S; Nizamov U; Abdullaeva G; Nagay A
Atherosclerosis; 2018 Oct; 277():524-529. PubMed ID: 30270094
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins.
Rallidis LS; Triantafyllis AS; Tsirebolos G; Katsaras D; Rallidi M; Moutsatsou P; Lekakis J
Atherosclerosis; 2016 Jun; 249():17-21. PubMed ID: 27062405
[TBL] [Abstract][Full Text] [Related]
12. Familial Hypercholesterolemia, Familial Combined Hyperlipidemia, and Elevated Lipoprotein(a) in Patients With Premature Coronary Artery Disease.
Vikulova DN; Trinder M; Mancini GBJ; Pimstone SN; Brunham LR
Can J Cardiol; 2021 Nov; 37(11):1733-1742. PubMed ID: 34455025
[TBL] [Abstract][Full Text] [Related]
13. Endothelial dysfunction, but not structural atherosclerosis, is evident early in children with heterozygous familial hypercholesterolemia.
Vlahos AP; Naka KK; Bechlioulis A; Theoharis P; Vakalis K; Moutzouri E; Miltiadous G; Michalis LK; Siamopoulou-Mavridou A; Elisaf M; Milionis HJ
Pediatr Cardiol; 2014 Jan; 35(1):63-70. PubMed ID: 23821294
[TBL] [Abstract][Full Text] [Related]
14. Coronary computed tomographic angiographic findings in asymptomatic patients with heterozygous familial hypercholesterolemia and null allele low-density lipoprotein receptor mutations.
Viladés Medel D; Leta Petracca R; Carreras Costa F; Cardona Olle M; Barros Membrilla A; Hidalgo Perez JA; Pujadas Olano S; Alomar Serrallach X; Franco Peral M; Pons-Lladó G
Am J Cardiol; 2013 Apr; 111(7):955-61. PubMed ID: 23340035
[TBL] [Abstract][Full Text] [Related]
15. Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients.
Pérez-Calahorra S; Sánchez-Hernández RM; Plana N; Marco-Benedi V; Pedro-Botet J; Almagro F; Brea A; Ascaso JF; Lahoz C; Civeira F;
Am J Cardiol; 2017 Mar; 119(5):742-748. PubMed ID: 28081939
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, risk factor burden, and severity of coronary artery disease in patients with heterozygous familial hypercholesterolemia hospitalized for an acute myocardial infarction: Data from the French RICO survey.
Farnier M; Salignon-Vernay C; Yao H; Chague F; Brunel P; Maza M; Brunet D; Bichat F; Beer JC; Cottin Y; Zeller M
J Clin Lipidol; 2019; 13(4):601-607. PubMed ID: 31324593
[TBL] [Abstract][Full Text] [Related]
18. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy.
Vishwanath R; Hemphill LC
J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels.
Funabashi S; Kataoka Y; Hori M; Ogura M; Doi T; Noguchi T; Harada-Shiba M
J Am Heart Assoc; 2022 Aug; 11(16):e025232. PubMed ID: 35929461
[TBL] [Abstract][Full Text] [Related]
20. The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.
Cao YX; Liu HH; Sun D; Jin JL; Xu RX; Guo YL; Wu NQ; Zhu CG; Li S; Zhang Y; Sun J; Li JJ
Atherosclerosis; 2018 Oct; 277():7-14. PubMed ID: 30170223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
